RESUMO
Incidence of white matter injury (WMI), which is featured as softening of white matter tissues, has recently increased. Previous studies have demonstrated a close correlation between T helper cell 1 and T helper cell 2 (Th1/Th2) imbalance and nuclear factorκB (NFκB) with brain disease. Their role in premature WMI, however, remains to be illustrated. Serum samples were collected from 60 premature WMI neonates, plus another control group of 60 premature babies without WMI. Patients were further divided into mild, moderate and severe WMI groups. Reverse transcription quantitative polymerase chain reaction was used to test mRNA expression levels of Th1/Th2 cytokines, including interleukin 2 (IL)2, tumor necrosis factorα (TNFα), IL4, IL10 and nuclear factor (NF)κB, whilst their serum levels were measured by ELISA. Their correlation with disease occurrence and progression were further analysed, to illustrate the effect of Th1/Th2 balance and NFκB on pathology of premature WMI. Serum levels of IL4 and IL10 were significantly decreased in premature WMI babies, whilst IL2, TNFα and NFκB were upregulated (P<0.05 vs. control group). With aggravated disease, IL4 and IL10 expression was further decreased while IL2, TNFα and NFκB were increased (P<0.05 vs. mild WMI group). Th1 cytokines IL2 and TNFα and NFκB were negatively correlated with Th2 cytokines IL4 and IL10. Disease severity was positively correlated with IL2, TNFα and NFκB expression, and was negatively correlated with IL4 and IL10 (P<0.05). Th1/Th2 imbalance and NFκB upregulation were observed in WMI pathogenesis, with elevated secretion of Th1 cytokines and decreased Th2 cytokines, suggesting that Th1/Th2 imbalance and NFκB upregulation may be a potential indicator for the early diagnosis and treatment of WMI pathogenesis and progression.
Assuntos
NF-kappa B/metabolismo , Nascimento Prematuro , Células Th1/metabolismo , Células Th2/metabolismo , Substância Branca/metabolismo , Lesões Encefálicas/diagnóstico , Lesões Encefálicas/etiologia , Lesões Encefálicas/metabolismo , Citocinas/sangue , Citocinas/genética , Citocinas/metabolismo , Ensaio de Imunoadsorção Enzimática , Feminino , Perfilação da Expressão Gênica , Humanos , Recém-Nascido , Masculino , Índice de Gravidade de Doença , Células Th1/imunologia , Células Th2/imunologia , Transcriptoma , Substância Branca/imunologia , Substância Branca/lesõesRESUMO
The aim of the present study was to investigate the protective effects of miconazole on myelin sheaths following cerebral white matter damage (WMD) in premature infant rats. Sprague Dawley rats (3-days-old) were randomly divided into four groups (n=30 each) as follows: Sham surgery group, WMD model group, 10 mg/kg/day treatment group and 40 mg/kg/day treatment group. A cerebral white matter lesion model was created by ligating the right common carotid artery for 80 min. Treatment groups were administered with 10 or 40 mg/kg miconazole at 4-8 days following birth (early treatment group) or 5-11 days following birth (late treatment group). Rats in the model group received the same concentration of dimethylsulfoxide. Myelin basic protein (MBP) immunohistochemical staining and western blotting were used to detect the expression of cerebral white matter-specific MBP, and changes in myelin structure were observed using transmission electron microscopy. No swelling or necrosis was observed in the corpus callosum of the sham group rats, whereas rats in the model group demonstrated edema, loose structure, fiber disorder, inflammatory gliocytes and selective white matter lesions. Following treatment with miconazole, MBP expression in the corpus callosum was significantly higher compared with the model group. Furthermore, in the model group, myelin sheaths in the corpus callosum were loose with small vacuoles, there was a marked decrease in thickness and structural damage was observed. Conversely, a marked improvement in myelination was observed in the treatment group. The results of the present study suggest that miconazole is able to promote formation of the myelin sheath to ameliorate premature cerebral white matter lesions caused by ischemia or hypoxia in rats.